Abstract:RATIONALE:Sustained cardiac hypertrophy is often accompanied by maladaptive cardiac remodeling leading to decreased compliance and increased risk for heart failure. Maladaptive hypertrophy is considered to be a therapeutic target for heart failure. MicroRNAs (miRNAs) and long noncoding RNAs (lncRNAs) have various biological functions and have been extensively investigated in past years.OBJECTIVE:We identified miR-489 and lncRNAs (cardiac hypertrophy related factor, CHRF) from hypertrophic cardiomyocytes. Here, we tested the hypothesis that miR-489 and CHRF can participate in the regulation of cardiac hypertrophy in vivo and in vitro.METHODS AND RESULTS:A microarray was performed to analyze miRNAs in response to angiotensin II treatment, and we found miR-489 was substantially reduced. Enforced expression of miR-489 in cardiomyocytes and transgenic overexpression of miR-489 both exhibited reduced hypertrophic response on angiotensin II treatment. We identified myeloid differentiation primary response gene 88 (Myd88) as a miR-489 target to mediate the function of miR-489 in cardiac hypertrophy. Knockdown of Myd88 in cardiomyocytes and Myd88-knockout mice both showed attenuated hypertrophic responses. Furthermore, we explored the molecular mechanism by which miR-489 expression is regulated and found that an lncRNA that we named CHRF acts as an endogenous sponge of miR-489, which downregulates miR-489 expression levels. CHRF is able to directly bind to miR-489 and regulate Myd88 expression and hypertrophy.CONCLUSIONS:Our present study reveals a novel cardiac hypertrophy regulating model that is composed of CHRF, miR-489, and Myd88. The modulation of their levels may provide a new approach for tackling cardiac hypertrophy.

LncRNA-Mhrt Regulates Cardiac Hypertrophy by Modulating the Mir-145A-5p/klf4/myocardin Axis.

Cardiac Hypertrophy and Dysfunction Induced by Overexpression of Mir-214 in Vivo

The Mechanism of Myocardial Hypertrophy Regulated by the Interaction Between Mhrt and Myocardin.

LncRNA TUG1 Alleviates Cardiac Hypertrophy by Targeting Mir‐34a/dkk1/wnt‐β‐catenin Signalling

The role of lncRNAKCNQ1OT1/miR-301b/Tcf7 axis in cardiac hypertrophy

MiR-466h-5p Induces Expression of Myocardin with Complementary Promoter Sequences

The Lncrna Plscr4 Controls Cardiac Hypertrophy by Regulating Mir-214

Mir-9 and NFATc3 Regulate Myocardin in Cardiac Hypertrophy

Myocardin-Related Transcription Factor-A Induces Cardiomyocyte Hypertrophy

The Long Noncoding RNA CHRF Regulates Cardiac Hypertrophy by Targeting Mir-489.

miR‐31‐5p suppresses myocardial hypertrophy by targeting Nfatc2ip

mir15a/mir16‐1 cluster and its novel targeting molecules negatively regulate cardiac hypertrophy

Knockdown of KCNQ1OT1 Attenuates Cardiac Hypertrophy Through Modulation of the Mir-2054/Akt3 Axis

Myeloid MKL1 Disseminates Cues to Promote Cardiac Hypertrophy in Mice

The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m6A RNA methylation reading protein Ythdf2

Microrna-340-5p Functions Downstream Of Cardiotrophin-1 To Regulate Cardiac Eccentric Hypertrophy And Heart Failure Via Target Gene Dystrophin

CircRNA Larp4b/miR-298-5p/Mef2c Regulates Cardiac Hypertrophy Induced by Angiotensin II

LncRNA‐MIAT Regulates Fibrosis in Hypertrophic Cardiomyopathy (HCM) by Mediating the Expression of Mir‐29a‐3p

The Expression Of Microrna In Adult Rat Heart With Isoproterenol-Induced Cardiac Hypertrophy

LncRNA MHRT Prevents Angiotensin II-Induced Myocardial Oxidative Stress and NLRP3 Inflammasome via Nrf2 Activation

MiR-27a-3p/Hoxa10 Axis Regulates Angiotensin II-Induced Cardiomyocyte Hypertrophy by Targeting Kv4.3 Expression